Intrinsic Therapeutics
Founded Year
2000Stage
Unattributed - II | AliveTotal Raised
$274.58MLast Raised
$5.91M | 2 mos agoAbout Intrinsic Therapeutics
Intrinsic Therapeutics develops medical devices. It offers a device to close large defects in the annulus and therapies for soft-tissue injuries of the spine. Intrinsic Therapeutics was formerly known as MedGenesis. It was founded in 2000 and is based in Woburn, Massachusetts.
Missing: Intrinsic Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Intrinsic Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Intrinsic Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Intrinsic Therapeutics is included in 2 Expert Collections, including Medical Devices.
Medical Devices
8,928 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,901 items
Intrinsic Therapeutics Patents
Intrinsic Therapeutics has filed 38 patents.
The 3 most popular patent topics include:
- Bones of the vertebral column
- Bones of the thorax
- Dosage forms
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/8/2019 | 11/30/2021 | Bones of the vertebral column, Medical equipment, Dosage forms, Drug delivery devices, Implants (medicine) | Grant |
Application Date | 11/8/2019 |
|---|---|
Grant Date | 11/30/2021 |
Title | |
Related Topics | Bones of the vertebral column, Medical equipment, Dosage forms, Drug delivery devices, Implants (medicine) |
Status | Grant |
Latest Intrinsic Therapeutics News
Mar 3, 2022
Synlogic (NASDAQ: SYBX ) has appointed Michael Jensen as CFO. Mr. Jensen, most recently served as the CFO at Intrinsic Therapeutics, a commercial-stage medical device company focused on delivering treatments to improve surgical efficacy. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Intrinsic Therapeutics Frequently Asked Questions (FAQ)
When was Intrinsic Therapeutics founded?
Intrinsic Therapeutics was founded in 2000.
Where is Intrinsic Therapeutics's headquarters?
Intrinsic Therapeutics's headquarters is located at 30 Commerce Way, Woburn.
What is Intrinsic Therapeutics's latest funding round?
Intrinsic Therapeutics's latest funding round is Unattributed - II.
How much did Intrinsic Therapeutics raise?
Intrinsic Therapeutics raised a total of $274.58M.
Who are the investors of Intrinsic Therapeutics?
Investors of Intrinsic Therapeutics include Questa Capital, Delos Capital, New Enterprise Associates, Epidarex Capital, Paycheck Protection Program and 10 more.
Who are Intrinsic Therapeutics's competitors?
Competitors of Intrinsic Therapeutics include SynergEyes, MedShape, FzioMed, Mobius Therapeutics, Mercator MedSystems and 10 more.
Compare Intrinsic Therapeutics to Competitors
Biopharmaceutical products for the of spinal cord injuries and other central nervous system disorders.
Haemechanics has developed a synthetic, hemostatic material capable of simultaneously inducing blood clotting and delivering therapeutics. The material is able to induce clotting as effectively as biologically based products, at a fraction of the price.
OrthoMimetics aiming to bring to market a line of products for the regenerative repair of cartilage, ligament and tendon injuries.
aims to provide customized genetic assessments of inherited susceptibility to age-related disorders.
Medical devices for the treatment of severe gastrointestinal disorders
Vitreo Retinal Technologies, Inc. is developing therapeutics for the treatment of serious ocular diseases.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.